Join
Live feed
·
PRReleasevia Quantisnow
G1 Therapeutics Inc. logo

G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)

ByQuantisnow·Wall Street's wire, on your screen.
GTHX· G1 Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GTHX (G1 Therapeutics Inc.) and more on Quantisnow.